The Conversation (0)
Theralase Technologies shared an interim data set of the four patients being treated with TLD-1433, in a Phase Ib Non-Muscle Invasive Bladder Cancer clinical study.
Theralase Technologies (TSXV:TLT; OTCQX:TLTFF) shared an interim data set of the four patients being treated with TLD-1433, in a Phase Ib Non-Muscle Invasive Bladder Cancer clinical study.
As quoted in the press release:
The Study entitled, “A Phase Ib Trial of Intravesical Photo Dynamic Therapy (“PDT“) in Patients with NMIBC at High Risk of Progression, Who are Refractory to Therapy with Bacillus Calmette-Guerin (“BCG“) and Who are Medically Unfit for or Refuse a Cystectomy” commenced treating patients in March 2017 and to date has treated three patients at the Maximum Recommended Starting Dose (“MRSD“) (0.35 mg/cm2) and one patient at the Therapeutic Dose (0.70 mg/cm2) of TLD-1433 PDC, activated by laser light (525 nm, 90 J/cm2) delivered through a combination of the TLC-3200 PDT Medical Laser and TLC-3400 Laser Probe Dosimetry Fibre Optic Cage (“DFOC“) technology.
Click here to read the full press release.
Source: www.accesswire.com